The purpose of the present work was to ascertain whether or not the hydroxylation of phenformin was controlled by a genetic polymorphism.
A polymorphism in the alicyclic 4-hydroxylation of the hypotensive drug debrisoquine has been described.' The study of selected families has indicated that poor hydroxylators of debrisoquine are autosomal Mendelian recessives, while the extensive hydroxylators are dominant. 2 Phenformin is a biguanide that was formerly used as an oral hypoglycaemic agent in maturity onset diabetes. It is rapidly absorbed in man and metabolised exclusively by p-hydroxylation to a single metabolite, 4-hydroxy-phenformin.3 The unchanged drug and its metabolite are cleared from the blood virtually exclusively by the kidneys. About twothirds of an oral dose is excreted in the urine within eight hours as the unchanged drug plus its metabolite.
The purpose of the present work was to ascertain whether or not the hydroxylation of phenformin was controlled by a genetic polymorphism.
The study was approved by the Ethics Committee of St Mary's Hospital, London, and every participant gave his or her fully informed consent.
Methods

VOLUNTEERS
A total of 195 unrelated volunteers participated in the study. These were recruited from the staff and students of St Mary's Hospital and Medical School. More than a week later, 51 of these 195 volunteers, selected at random, were studied again. A total of 87 close relatives of 27 of these 51 volunteers, again selected at random, also participated in the study. This ratio is entirely analogous to the 'metabolic ratio' used in the studies on the oxidation of debrisoquine. This index not only allows estimation of drug oxidation capacity but it also avoids the complications arising from differences in total urinary recovery of drug related products. family members) have previously been published but without genetic analysis5 ( fig 3) . The index numbers used here are the same as in the previous publication. One additional sib of the proband in '2 males and 123 family 7 consented later to participate. She had a PR -s) of their ages, of 4-5 and is included in the calculations that follow. weights, and heights were 22-3 (18 to 52) years, 63-4 (41 to 146) kg, and 1705 (152 to 198) cm, respectively. The urinary recovery of phenformin plus 4-hydroxy-phenformin varied from 9-8 to 89-6% of the ingested dose. There was also a marked interindividual variation in phenformin oxidation capacity as judged by the phenformin ratio which ranged from 0-9 to 184. The details of the volunteers together with their corresponding urinary recoveries of phenformin and 4-hydroxyphenformin and phenformin oxidation capacity have previously been published.5 6 The repeatability experiment on 51 subjects where PR was measured on two separate occasions yielded a Spearman rank correlation, rs, of 0-97 (p<0.0001) ( dominants is in doubt) was 1-1847±0-0906. The (1) The identical twins in family 24 are both of the difference between the means was highly significant same oxidation phenotype.
(t=7.7; p<0-001) which indicates a substantial (2) Observation of families 5, 9, and 20 exclude the degree of dominance. 
